These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3915881)

  • 21. [Efficacy of an etofylline-cyclandelate combination in age-dependent cerebrovascular insufficiency].
    Foltyn P; Lücker PW; Schnitker J
    Arzneimittelforschung; 1982; 32(10):1322-8. PubMed ID: 6891235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific effects of cyclandelate on memory.
    Ananth J
    Drugs; 1987; 33 Suppl 2():97-102. PubMed ID: 3622311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of a combined anti-ischemic and anticholinergic substance with antidepressant properties.
    Brasseur R
    Angiology; 1978 Feb; 29(2):121-32. PubMed ID: 646177
    [No Abstract]   [Full Text] [Related]  

  • 26. Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs.
    Reich T
    J Am Geriatr Soc; 1977 May; 25(5):202-5. PubMed ID: 853204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determination of the anti-anoxia capacity of drugs].
    Truchaud M
    Sem Hop Ther; 1977 Nov; 53(9):425-9. PubMed ID: 341317
    [No Abstract]   [Full Text] [Related]  

  • 28. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of cyclospasmol on early diabetic retinopathy.
    Mota MC; Leite E; Ruas MA; Verjans HL; Blakemore CB; Cunha-Vaz JG
    Int Ophthalmol; 1987 Feb; 10(1):3-9. PubMed ID: 3549595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclandelate: calcium modulation and clinical effects. Proceedings of a symposium. Helsinki, 14-15 November, 1986.
    Drugs; 1987; 33 Suppl 2():1-141. PubMed ID: 3622302
    [No Abstract]   [Full Text] [Related]  

  • 32. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride.
    Bary PR; Moisey CU; Stephenson TP; Brendler CB
    Prog Clin Biol Res; 1981; 78():313-9. PubMed ID: 7038709
    [No Abstract]   [Full Text] [Related]  

  • 33. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parasympatholytic agents in duodenal ulcer. Double-blind controlled trial with oxyphencyclimine hydrochloride.
    Goyal RK; Bhardwaj OP; Chuttani HK
    J Indian Med Assoc; 1968 Apr; 50(8):365-7. PubMed ID: 4874902
    [No Abstract]   [Full Text] [Related]  

  • 36. Pegaptanib: new drug. In macular degeneration: too many risks for too little benefit.
    Prescrire Int; 2006 Aug; 15(84):127-9. PubMed ID: 16989023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclandelate and mental functions: a double-blind cross-over trial in normal elderly subjects.
    Judge TG; Urquhart A; Blakemore CB
    Age Ageing; 1973 May; 2(2):121-4. PubMed ID: 4591604
    [No Abstract]   [Full Text] [Related]  

  • 38. Modes and mechanisms of action of vasoactive drugs and especially of cyclandelate.
    Timmerman H
    Br J Clin Pract Suppl; 1984; 34():10-9. PubMed ID: 6430317
    [No Abstract]   [Full Text] [Related]  

  • 39. Calcium modulation and clinical effect. Profile of cyclandelate.
    Timmerman H
    Drugs; 1987; 33 Suppl 2():1-4. PubMed ID: 3622303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical trials of using Cavinton in the form of intravenous infusion in the treatment of macular degeneration].
    Gerkowicz K; Toczołowski J; Jedrzejewski D; Jankowska I; Szponar B
    Klin Oczna; 1987 Mar; 89(3):95-6. PubMed ID: 3309450
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.